Rituximab as maintenance therapy for patients with follicular lymphoma

Primary cutaneous follicle center lymphoma in the setting of chronic lymphocytic leukemia

“…[9] Rituximab in combination with chemotherapy improves overall survival compared to chemotherapy alone in patients receiving induction and maintenance therapy for newly diagnosed or relapsed PCFCL. [10] This treatment regimen can also be an effective induction therapy for CLL, as documented in our patient.…”

Primary cutaneous follicle center lymphoma in the setting of chronic lymphocytic leukemia

“…[9] Rituximab in combination with chemotherapy improves overall survival compared to chemotherapy alone in patients receiving induction and maintenance therapy for newly diagnosed or relapsed PCFCL. [10] This treatment regimen can also be an effective induction therapy for CLL, as documented in our patient.…”

Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States

“…13 A 2009 meta-analysis of randomized controlled studies showed that rituximab use significantly increased the risk of infection in adult patients with follicular lymphoma; the risk was more pronounced when only grade 3 or 4 infections were included in the analysis. 14 In contrast, an open-label extension analysis of 3 double-blind trials of adult patients with rheumatoid arthritis revealed no significant increase in the risk of infections after rituximab use. 3 Kelesidis et al 13 reported that the infectious safety profile of rituximab is better in adult patients with autoimmune diseases than in those with lymphoma.…”

Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges

“…To our knowledge, it has not yet been systematically evaluated if a maintenance therapy with rituximab monotherapy during the state of complete remission prevents tumor relapse of PCLBCL, as described for systemic B‐cell lymphoma [23]. For systemic B‐cell lymphoma rituximab maintenance significantly improves progression‐free survival compared to observation in large prospective clinical trials [24]. However, only limited case series have described the use of rituximab application as a maintenance therapy for disease‐free primary cutaneous B‐cell lymphoma [25] and exact dosing of rituximab and adequate treatment intervals are unknown.…”

Primary cutaneous follicle center lymphoma in the setting of chronic lymphocytic leukemia

“…[9] Rituximab in combination with chemotherapy improves overall survival compared to chemotherapy alone in patients receiving induction and maintenance therapy for newly diagnosed or relapsed PCFCL. [10] This treatment regimen can also be an effective induction therapy for CLL, as documented in our patient.…”

Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States

“…13 A 2009 meta-analysis of randomized controlled studies showed that rituximab use significantly increased the risk of infection in adult patients with follicular lymphoma; the risk was more pronounced when only grade 3 or 4 infections were included in the analysis. 14 In contrast, an open-label extension analysis of 3 double-blind trials of adult patients with rheumatoid arthritis revealed no significant increase in the risk of infections after rituximab use. 3 Kelesidis et al 13 reported that the infectious safety profile of rituximab is better in adult patients with autoimmune diseases than in those with lymphoma.…”

Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges

“…To our knowledge, it has not yet been systematically evaluated if a maintenance therapy with rituximab monotherapy during the state of complete remission prevents tumor relapse of PCLBCL, as described for systemic B‐cell lymphoma [23]. For systemic B‐cell lymphoma rituximab maintenance significantly improves progression‐free survival compared to observation in large prospective clinical trials [24]. However, only limited case series have described the use of rituximab application as a maintenance therapy for disease‐free primary cutaneous B‐cell lymphoma [25] and exact dosing of rituximab and adequate treatment intervals are unknown.…”

Primary cutaneous follicle center lymphoma in the setting of chronic lymphocytic leukemia

“…[9] Rituximab in combination with chemotherapy improves overall survival compared to chemotherapy alone in patients receiving induction and maintenance therapy for newly diagnosed or relapsed PCFCL. [10] This treatment regimen can also be an effective induction therapy for CLL, as documented in our patient.…”

Leveraging Administrative Data to Monitor Rituximab Use in 2875 Patients at 42 Freestanding Children's Hospitals across the United States

“…13 A 2009 meta-analysis of randomized controlled studies showed that rituximab use significantly increased the risk of infection in adult patients with follicular lymphoma; the risk was more pronounced when only grade 3 or 4 infections were included in the analysis. 14 In contrast, an open-label extension analysis of 3 double-blind trials of adult patients with rheumatoid arthritis revealed no significant increase in the risk of infections after rituximab use. 3 Kelesidis et al 13 reported that the infectious safety profile of rituximab is better in adult patients with autoimmune diseases than in those with lymphoma.…”

Primary cutaneous diffuse large B-cell lymphoma, leg-type, treated with a modified R-CHOP immunochemotherapy - diagnostic and therapeutic challenges

“…To our knowledge, it has not yet been systematically evaluated if a maintenance therapy with rituximab monotherapy during the state of complete remission prevents tumor relapse of PCLBCL, as described for systemic B‐cell lymphoma [23]. For systemic B‐cell lymphoma rituximab maintenance significantly improves progression‐free survival compared to observation in large prospective clinical trials [24]. However, only limited case series have described the use of rituximab application as a maintenance therapy for disease‐free primary cutaneous B‐cell lymphoma [25] and exact dosing of rituximab and adequate treatment intervals are unknown.…”